CN1660198A - Medication for treating cholecystitis and cholelithiasis, and preparation method - Google Patents
Medication for treating cholecystitis and cholelithiasis, and preparation method Download PDFInfo
- Publication number
- CN1660198A CN1660198A CN 200410061337 CN200410061337A CN1660198A CN 1660198 A CN1660198 A CN 1660198A CN 200410061337 CN200410061337 CN 200410061337 CN 200410061337 A CN200410061337 A CN 200410061337A CN 1660198 A CN1660198 A CN 1660198A
- Authority
- CN
- China
- Prior art keywords
- fructus gardeniae
- medicine
- cholelithiasis
- iridoid glycoside
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
A Chinese medicine in the form of capsule, tablet, dripping pile, injection, etc for treating cholecystitis and cholelithiasis is prepared from capejasmine fruit through extracting in water or alcohol, separating and purifying by macroreticular resin.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of cholecystitis, cholelithiasis and preparation method thereof, particularly relate to a kind of Chinese medicine preparation that contains the Fructus Gardeniae iridoid glycoside composition, this medicine has good curative effect to the treatment of cholecystitis, cholelithiasis, and the present invention also provides the preparation method of this medicine.
Background technology
Cholecystitis, cholelithiasis be in, a kind of commonly encountered diseases of old people, frequently-occurring disease.Most of cholecystitis are all closely related with cholelithiasis, and about 95% chronic cholecystitis patient is simultaneously with calculus.The sickness rate of cholecystitis, cholelithiasis is ascendant trend year by year in recent years, and is more obvious with the big city especially; In addition, the probability that middle-aged and elderly people is got fat increases year by year, because fat metabolic disturbance, the sickness rate of cholecystitis obviously increases.Statistics show that the sickness rate of cholecystitis and cholelithiasis accounts for about 15% of total population, is more common in 35～45 years old middle age, and the people's sickness rate more than 60 years old is 28%.Cholecystitis can also cause other complication, can increase the weight of or bring out coronary heart disease, causes that myocardial ischemia sexually revises; Simultaneously can bring out carcinoma of gallbladder, pancreatitis etc.
The domestic and international at present treatment to primary disease still lacks medicine efficiently, and this disease of western medicine has only the effect of 30-60%, and toxic and side effects is strong; Though surgical result is good, brings great misery to patient, and very easily produce bad postoperative complication; Various soup sides, patent medicine method of treatment kind are more, but curative effect is not obvious, and the Chinese patent medicine of therefore developing a kind of efficient, safety, taking convenience, no bad side effect is the purpose that we invent.
Fructus Gardeniae is called Yellow Fructus Gardeniae, Fructus Gardeniae, SHANZHIZI, derives from the mature fruit of Maguireothamnus speciosus Fructus Gardeniae (Gardeniajasminoides Ellis), cold in nature, bitter in the mouth, GUIXIN, liver, lung, stomach, tri-jiao channel have effects such as pathogenic fire purging relieving restlessness, clearing away heat and promoting diuresis, removing pathogenic heat from blood and toxic substance from the body.There is cultivation in most of area, the whole nation, mainly is distributed in Jiangxi, Hunan, Zhejiang, Fujian, Sichuan.Beginning is stated from Shennong's Herbal, after this all has in successive dynasties book on Chinese herbal medicine, the hospital to discuss and replenish.How vexed in order to calentura, jaundice dark coloured urine, blood strangury and dry pain, heat in blood are told and are hesitated, conjunctival congestion and swelling pain, fire-toxin storehouse infections, sprain etc.Clinical in the existing history for many years of traditional hepatic cholagogic Chinese medicine, be mainly used in icterohepatitis, cholecystitis etc.
Fructus Gardeniae mainly contains iridoid glycosides such as jasminoidin (geniposide), Gardenoside etc., Diterpenes composition such as crocin, crocetin etc., triterpenes, flavonoid, polysaccharide etc.Wherein iridoid glycoside constituents jasminoidin is the main active of Fructus Gardeniae.Recent study shows, Fructus Gardeniae has tangible gallbladder contraction, contained iridoid glycosides has tangible choleretic effect in its fruit, the ethanol extract of fruit can make choleresis increase, give geniposide (jasminoidin) to rat in duodenum, behind the 2h bile secretion is significant persistence facilitation.Experiment shows that the low dosage jasminoidin can significantly increase bile flow, and is identical with the sodium dehydrocholate effect or it was arranged.Fructus Gardeniae gives birth to having tangible antiinflammatory action, can obviously suppress Oleum Tiglii induced mice auricular concha inflammation and reduce acetic acid induced mice abdominal cavity capillary permeability.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine medicine for the treatment of cholecystitis, cholelithiasis, effective ingredient wherein is the iridoid glycoside compounds from Fructus Gardeniae, i.e. Fructus Gardeniae total iridoid glycosides.
Having the present invention further provides with described Fructus Gardeniae total iridoid glycosides extract is active component, is used for the treatment of the Chinese medicine pharmaceutical preparation and the related dose forms of cholecystitis, cholelithiasis.
Another object of the present invention is to be provided for treat the preparation method of this Chinese medicine medicine of cholecystitis, cholelithiasis, Fructus Gardeniae total iridoid glycosides preparation method of extract particularly, this method good reproducibility, good stability, and the yield height of raw material, cost is low, is fit to suitability for industrialized production.
Purpose of the present invention can reach by following measure:
Get the Fructus Gardeniae medical material, water or ethanol extraction, merge extractive liquid, filters, and concentrated extracting solution is to finite concentration, after leaving standstill, separation and purification, the polystyrene macroporous adsorptive resins of having handled well on the extracting centrifugal liquid, first water eluting impurity, the reuse ethanol elution is collected eluent, concentrates drying.
Purpose of the present invention can also reach by following measure:
1) with after the pulverizing medicinal materials, add the water of 5～20 times of amounts or the ethanol extraction of 50%～85% concentration respectively, preferably to extract 1～3 time, each extraction time was advisable with 1～3 hour.
2) concentrated extracting solution is to medical material: medicinal liquid=3: 1～1: 5, preferred medical material: medicinal liquid=1: 3;
3) after the extracting solution after above-mentioned the concentrating left standstill, centrifugal or membrance separation was made with extra care extracting centrifugal liquid;
4) get the polystyrene macroporous adsorptive resins of having handled well on the above-mentioned centrifugal liquid, first water elution impurity, 30%～85% ethanol elution of 1～5 times of column volume amount of reuse with 0.5～3 times of column volume amount, collect eluent, concentrate, drying promptly gets the iridoid glucoside extract.
The macroporous adsorptive resins purification is obtained very good effect on the extracting solution of the present invention, and total content improves greatly.Studies show that in a large number AB-8, D301R, HPD100, HPD400 macroporous resin are best to the adsorbing separation effect of Fructus Gardeniae iridoid glycoside.
In the Fructus Gardeniae iridoid glycoside extract that employing the present invention makes, the content of iridoid glycoside is at least 50%, and its main active is a jasminoidin, and by high effective liquid chromatography for measuring, the content of jasminoidin can reach more than 30%.
On this basis, the present invention also provides a kind of Chinese medicine pharmaceutical preparation for the treatment of cholecystitis, cholelithiasis, this medicine is its effective active composition with above-mentioned Fructus Gardeniae total iridoid glycosides, and pharmaceutical preparation of the present invention comprises capsule, tablet, dispersible tablet, soft capsule, drop pill, injection.
The Fructus Gardeniae iridoid glycoside extract that the present invention makes, owing to adopted the macroporous adsorbent resin technology in the modernization of Chinese medicine technology, the content of active component is wherein improved, thereby improved curative effect, and a large amount of impurity have been removed, both solve the big problem of moisture absorption that Chinese patent medicine often has, reduced dose and toxic and side effects again.
Adopt the research of animal model below, further specify practicality of the present invention Fructus Gardeniae iridoid glycoside extract drug effect.
1, pharmacodynamic study
(1) lithocholic acid brings out the demonstration of Cavia porcellus cholecystitis model test: the 31-77.5mg/kg Fructus Gardeniae iridoid glycoside can reduce β in the rat bile-GCD activity (P＜0.05), reduce TB content (P＜0.01), TCH content (P＜0.01), Ca content (P＜0.05); Alleviate the steatosis of test Cavia porcellus liver, the inflammatory disorders of mucous membrane of gallbladder.
(2) test of rabbit cholesterol calculus shows: the 18.7-46.7mg/kg Fructus Gardeniae iridoid glycoside can reduce the gallstone formation rate (P＜0.05) of test rabbit, reduces bile TCH content (P＜0.01), improves the content (P＜0.05) of bile acid in the test lapin bile; Alleviate the steatosis and the hydropic degeneration of test rabbit liver, the inflammatory disorders of mucous membrane of gallbladder.
(3) the suppurative biliary tract infection test of rabbit shows: the 18.7-46.7mg/kg Fructus Gardeniae iridoid glycoside can reduce IBP (P＜0.05), reduction TB content (P＜0.01), CB content (P＜0.05), the TCH content (P＜0.05) of test rabbit; Alleviate congestion and edema, the inflammatory cell of expansion, the mucosa of test rabbit bile duct infiltration,, alleviate hepatocellular swelling, degeneration and inflammatory cell infiltration.
(4) test of external lithodialysis shows: 400 and 800mg/kg (adult's consumption every day) Fructus Gardeniae iridoid glycoside to the dissolution and UDCA suitable (P＞0.05) of calculus.
(5) function of gallbladder promoting test
1. the influence test to normal rat bile shows: the 36-90mg/kg Fructus Gardeniae iridoid glycoside can increase test rat gallbladder contraction frequency and bile flow, reduce TB content (P＜0.01), CB content (P＜0.01), TCH content (P＜0.01), the content (P＜0.05) of bile acid in the test rat bile that raises.
2. the influence test to APIT (phenyl isothiocyanate) hepatic injury rat bile shows: the 36-90mg/kg Fructus Gardeniae iridoid glycoside can increase the bile flow of test rat, reduce TB content (P＜0.05), CB content (P＜0.05), the content (P＜0.05) of bile acid in the test rat bile that raises.
(6) the antiinflammatory test shows: 52-130mg/kg Fructus Gardeniae iridoid glycoside xylol induced mice ear swelling has remarkable inhibitory action (P＜0.01).
Above pharmacodynamics test data shows that Fructus Gardeniae iridoid glycoside has effects such as anti-stone, calculus, lithodialysis, infection, hepatoprotective.
2, acute toxicity test
The toxicity of Fructus Gardeniae iridoid glycoside is low, can not survey LD50 in the trial test.The maximum dosage-feeding of mice and rat oral gavage administration is respectively 6000mg/kg/24h and 900mg/kg/24h, is equivalent to 450 times and 337.5 times of clinical oral administration dosage.Observed 7 days after irritating stomach, animal does not have death.After each perfusion was poured water, mice all end was found toxic reaction, and the mice autonomic activities is normal, do not see roll up, Folium Pini, lethargy phenomenon, secretions is not seen in nose, eye, oral cavity, defecates and does not see diarrhea with loose stool.Viewing duration, amount Celsius and the body weight of animal do not have obvious minimizing.After putting to death animal, all no abnormal discovery of perusal vitals (heart, liver, spleen, lung, kidney).
The acute toxicity tests shows that Fructus Gardeniae iridoid glycoside safe dose scope is bigger.
3, long term toxicity test
By 30,60,120 times intend clinical medicine doses establish low (100mg/kg), in (200mg/kg), high (400mg/kg) three dosage groups and distilled water matched group, successive administration 3 months, result of the test is: each dosage group of (1) Fructus Gardeniae iridoid glycoside and matched group are tested rat and no abnormality seens such as dead, its behavior, activity, quilt hair, feces all occurred in administration phase and convalescent period; High dose male rat the 5th all food-intakes and the apparent in view minimizing of matched group (P＜0.05), other each dosage group rat the administration phase and convalescent period food-intake and matched group relatively there are no significant difference (P＞0.05); High dose group male rat 3～15 all body weight and matched group is apparent in view alleviates (P＜0.05).In, low dose group male rat and each dosage group female rats the administration phase and convalescent period body weight and matched group relatively there are no significant difference (P＞0.05).(2) hematology detects, administration phase and convalescent period each dosage group and matched group relatively do not have significant difference; (3) blood biochemical measured value, administration phase and convalescent period each dosage group and matched group all relatively do not have significant difference; (4) system's postmortem, administration phase and convalescent period, each each internal organs of group test rat was not seen obvious naked eyes pathological changes; (5) histopathologic examination, the administration phase and convalescent period high dose group and matched group test rat do not see that tangible pathologic changes.The result shows that Fructus Gardeniae iridoid glycoside high dose (400mg/kg) successive administration 3 week back male rat body weight alleviate with matched group is apparent in view, and lasts till the convalescent period end always.In, low dose group is female and other each dosage group male rat does not all have tangible toxic reaction.
Above result of study shows that drug toxicity involved in the present invention is little, safe in utilization, has effects such as anti-stone, calculus, lithodialysis, infection, hepatoprotective, is a kind of have the treatment cholecystitis of good DEVELOPMENT PROSPECT, Chinese medicine preparation of cholelithiasis.
The specific embodiment
Embodiment 1:
The Fructus Gardeniae pulverizing medicinal materials is become coarse powder,, add 10 times of amounts at every turn and extracted 1.5 hours with 70% alcohol reflux 3 times, merge extractive liquid, reclaims ethanol, and is concentrated into medical material: medicinal liquid=1: 3, leave standstill, centrifugal, discard float and precipitation, the polystyrene macroporous adsorptive resins of having handled well on the extracting centrifugal liquid, first water elution impurity, 70% ethanol elution of 2.5 times of column volume amounts of reuse with 1.5 times of column volume amounts, collect eluent, concentrate, drying promptly gets the iridoid glucoside extract.Get Fructus Gardeniae iridoid glycoside extract 177g (containing total iridoid glycoside 133g), add appropriate amount of starch, magnesium stearate, adjust total amount to 250g, mixing divides the capsule of packing into to make 1000, promptly gets capsule dosage form of the present invention.
Embodiment 2:
Prepare the Fructus Gardeniae iridoid glycoside extract powder according to the method for embodiment 1, add appropriate amount of starch and magnesium stearate, mixing is granulated, drying, and tabletting promptly gets Tabules.
Embodiment 3:
Prepare the Fructus Gardeniae iridoid glycoside extract according to the method for embodiment 1, add filleies such as starch, microcrystalline Cellulose, disintegrating agent and micropowder silica gel or magnesium stearate such as carboxymethylstach sodium, polyvinylpolypyrrolidone, low-substituted hydroxypropyl cellulose, mixing is granulated drying, tabletting promptly gets tablet formulation.
Embodiment 4:
Preparing the Fructus Gardeniae iridoid glycoside extract according to the method for embodiment 1, add diluent mixings such as vegetable oil, Cera Flava or Polyethylene Glycol, is the capsule material with gelatin, glycerol, water etc., is pressed into soft capsule, promptly gets soft capsule dosage form.
Embodiment 5:
Preparing the Fructus Gardeniae iridoid glycoside extract according to the method for embodiment 1, add suitable diluent mixings such as Polyethylene Glycol, is coolant with paraffin etc., drips and makes drop pill, promptly gets drops.
Embodiment 6:
Prepare the Fructus Gardeniae iridoid glycoside extract according to the method for embodiment 1, behind distilled water diluting, carry out packing and sterilization, promptly get the injection dosage form.
Claims (12)
1. a medicine for the treatment of cholecystitis, cholelithiasis is characterized in that: the Fructus Gardeniae iridoid glycoside extract that extraction obtains from Fructus Gardeniae that contains effective dose.
2. the medicine of treatment cholecystitis according to claim 1, cholelithiasis is characterized in that: in the Fructus Gardeniae iridoid glycoside extract, iridoid glycoside content is at least 50%.
3. according to the medicine described in claim 1 or 2, it is characterized in that its dosage form comprises capsule, tablet, dispersible tablet, soft capsule, drop pill, injection.
4. the medicine of treatment cholecystitis according to claim 3, cholelithiasis is characterized in that: every or every mL contain drop pill, the injection of Fructus Gardeniae iridoid glycoside extract 5～50mg.
5. the medicine of treatment cholecystitis according to claim 3, cholelithiasis is characterized in that: every or every capsule, tablet, dispersible tablet, soft capsule that contains Fructus Gardeniae iridoid glycoside extract 50～300mg.
6. according to the preparation method of claim 1 or 3 described medicines, it is characterized in that may further comprise the steps: with Fructus Gardeniae Chinese medicine is raw material, ethanol extraction with 50%～85% concentration, separation and purification, purification, get the Fructus Gardeniae iridoid glycoside extract, be prepared into preparation according to practice of pharmacy with this extract.
7. preparation method according to claim 6 is characterized in that its method for preparing the Fructus Gardeniae iridoid glycoside extract may further comprise the steps:
1) water or ethanol extraction Fructus Gardeniae medical material;
2) concentrated extracting solution is to medical material: medicinal liquid=3: 1～1: 5;
3) after the extracting solution after above-mentioned the concentrating leaves standstill, centrifugal or membrance separation separation and purification, extracting centrifugal liquid;
4) get the polystyrene macroporous adsorptive resins of having handled well on the above-mentioned centrifugal liquid, first water eluting impurity, the reuse ethanol elution is collected eluent, concentrates, and drying promptly gets the iridoid glucoside extract.
8. method as claimed in claim 7, water or 50%～85% ethanol carry out the extraction of step (1).
9. method as claimed in claim 7 adopts the method for centrifugalize to make with extra care, and rotating speed is controlled to be 500 changes～20000 commentaries on classics.
10. method as claimed in claim 7 can also adopt the method for membrance separation to make with extra care, and the film kind comprises Flat Membrane, rolled film, inorganic ceramic film etc., and the molecular cut off scope is 500～30000.
11. the method for claim 1, wherein step (7) range of resin is silica gel, polyamide, ion exchange resin, macroporous adsorbent resin, and preferred macroporous adsorbent resin is best.
12. the application of medicine according to claim 1 in the medicine of preparation treatment cholecystitis, cholelithiasis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410061337XA CN1331475C (en) | 2004-12-14 | 2004-12-14 | Medication for treating cholecystitis and cholelithiasis, and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410061337XA CN1331475C (en) | 2004-12-14 | 2004-12-14 | Medication for treating cholecystitis and cholelithiasis, and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1660198A true CN1660198A (en) | 2005-08-31 |
| CN1331475C CN1331475C (en) | 2007-08-15 |
Family
ID=35009936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200410061337XA Expired - Fee Related CN1331475C (en) | 2004-12-14 | 2004-12-14 | Medication for treating cholecystitis and cholelithiasis, and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1331475C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1939458B (en) * | 2006-09-30 | 2010-05-19 | 福州大学 | Preparation of gardenia jasminoides by macroporous adsorbing resin |
| CN1939459B (en) * | 2006-09-30 | 2010-05-19 | 福州大学 | Preparation of gardenia jasminoides by membrane separation technology |
| CN102908384A (en) * | 2011-08-02 | 2013-02-06 | 苏州宝泽堂医药科技有限公司 | Method for purifying phlomis umbrosa turcz total iridoid glycoside |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100447148C (en) * | 2003-12-01 | 2008-12-31 | 李文军 | Cape jasmine extract , its preparing process and application |
-
2004
- 2004-12-14 CN CNB200410061337XA patent/CN1331475C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1939458B (en) * | 2006-09-30 | 2010-05-19 | 福州大学 | Preparation of gardenia jasminoides by macroporous adsorbing resin |
| CN1939459B (en) * | 2006-09-30 | 2010-05-19 | 福州大学 | Preparation of gardenia jasminoides by membrane separation technology |
| CN102908384A (en) * | 2011-08-02 | 2013-02-06 | 苏州宝泽堂医药科技有限公司 | Method for purifying phlomis umbrosa turcz total iridoid glycoside |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1331475C (en) | 2007-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10624938B2 (en) | Total flavone extract of flower of abelmoschus manihot L. medic and preparation method thereof | |
| US20060233896A1 (en) | Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, Cistanche tubulosa (Schenk.) Wight, process of making the same, and uses of the same | |
| US20070111955A1 (en) | Extraction and purification method of active constituents from stem of Lonicera japonica Thunb., its usage for anti-inflammatory and analgesic drug | |
| WO2018058261A1 (en) | Traditional chinese medicine composition for treating psoriasis and preparation method thereof | |
| CN101491611B (en) | Preparation method of serissa extract and use thereof | |
| CN106336445B (en) | The preparation method and application of compound 20 (R) ginseng sapoglycoside Rg 3 | |
| WO2011044751A1 (en) | Foliamangiferosides, preparation method and use thereof | |
| CN101810715A (en) | New application of fructus evodiae and extracts and compounds thereof | |
| CN100534508C (en) | Method for extracting effective sites group of smilax China root | |
| CN103479688B (en) | A kind of pharmaceutical composition Preparation Method And The Use for the treatment of rheumatoid arthritis | |
| WO2008145064A1 (en) | The method for a sequoyitol-containing extract obtaining from the genus of trifolium, sobyean and ginkgo biloba and use thereof | |
| CN101234159A (en) | Pharmaceutical combination with synergistic reaction | |
| CN1327875C (en) | Chinese medicine formulation for treating chronic pelvic inflammation and its preparing method | |
| CN102309542A (en) | Orthosiphon n-butanol fraction medicine for treating chronic nephritis and preparation method thereof | |
| CN1331475C (en) | Medication for treating cholecystitis and cholelithiasis, and preparation method | |
| CN102362877B (en) | Application of Pouzolzia extract | |
| CN101822705A (en) | Total platycodin and application of monomer platycodin D in antialcoholic drugs | |
| CN105535152B (en) | Application of loquat leaf total sesquiterpene extract | |
| WO2013138964A1 (en) | Application of iso-daphnetin compound in preparation of anti-diabetic medicines | |
| AU2019100730A4 (en) | Use of Composition of Sunflower Head, Gorgon Euryale Seed and Kudzuvine Root in Lowering Uric Acid and Repair of Liver and Kidney Injury | |
| CN112717031A (en) | Pharmaceutical composition for treating Alzheimer's disease and preparation method thereof | |
| CN102302545A (en) | Dai medicine extract with blood-sugar reducing activity, preparation method, composition and application | |
| CN101884700A (en) | Tea-containing Chinese medicinal composition | |
| CN101721450B (en) | Application of oriental cocklebur root chloroform extract used for treating peritonitis | |
| EP1498131A1 (en) | Medicinal preparation containing phenylethanoid glycosides extracted from Cistanche tubulosa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070815 Termination date: 20100114 |